The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines

European Journal of Pharmacology

Volumn 549, Issue 1-3, 2006, Pages 9-18

  Savickiene, Jurate ^a   Borutinskaite, Veronika Viktorija ^a,b   Treigyte, Grazina ^a   Magnusson, Karl Eric ^b   Navakauskiene, Ruta ^a  

^a VILNIUS UNIVERSITY   (Lithuania)

^b Department of Molecular and Clinical Medicine ^*  (Sweden)

Author keywords

Apoptosis; Differentiation; Histone deacetylase inhibitor; Leukemia; Transcription factors

Indexed keywords

BML 210; FAS LIGAND; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N (2 AMINOPHENYL) N' PHENYLOCTANOLDIAMINE; PROTEIN P21; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ACETYLATION; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CELL STRAIN K 562; DOSE RESPONSE; DRUG EFFECT; ERYTHROCYTE; GENE CONTROL; GENE EXPRESSION; GRANULOCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

ACETYLATION; ANILIDES; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CYTOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA; NF-KAPPA B; PROTEIN BINDING; TIME FACTORS; TRANSCRIPTION FACTORS; TRETINOIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33748958614     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.08.010     Document Type: Article

References (54)

1. Adam E., Quivy V., Bex F., Chariot A., Collette Y., Vanhulle C., Schoonbroodt S., Goffin V., Nguyen T.L., Gloire G., Carrard G., Friguet B., De Launoit Y., Burny A., Bours V., Piette J., and Van Lint C. Potentiation of tumor necrosis factor-induced NF-kappa B activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of I kappa B alpha. Mol. Cell. Biol. 23 (2003) 6200-6209
2. Bernhard D., Ausserlechner M.J., Tonko M., Loffler M., Hartmann B.L., Csordas A., and Kofler R. Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts. FASEB J. 13 (1999) 1991-2001
3. Bernhard D., Skvortsov S., Tinhofer I., Hubl H., Greil R., Csordas A., and Kofler R. Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts. Cell Death Differ. 8 (2001) 1014-1021
4. Calonghi N., Cappadone C., Pagnotta E., Boga C., Bertucci C., Fiori J., Tasco G., Casadio R., and Masotti L. Histone deacetylase 1: a target of 9-hydroxystearic acid in the inhibition of cell growth in human colon cancer. J. Lipid Res. 46 (2005) 1596-1603
5. Collins S. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation and cellular oncogene expression. Blood 70 (1987) 1233-1244
6. Chambers A.E., Banerjee S., Chaplin T., Dunne J., Debernardi S., Joel S.P., and Young B.D. Histone acetylation-mediated regulation of genes in leukaemic cells. Eur. J. Cancer 39 (2003) 1165-1175
7. Chen L.F., and Greene W.C. Regulation of distinct biological activities of the NF-kappa B transcription factor complex by acetylation. J. Mol. Med. 81 (2003) 549-557
8. Dai Y., Rahmani M., and Grant S. An intact NF-kappa B pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells. Cell Cycle 2 (2003) 462-472
9. Dornan D., Shimizu H., Burch L., Smith A.J., and Hupp T.R. The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53. Mol. Cell. Biol. 23 (2003) 8846-8861
10. Fischle W., Wang Y., and Allis C.D. Histone and chromatin cross-talk. Curr. Opin. Cell. Biol. 15 (2003) 172-183
11. (WAF1/CIP1) gene. Exp. Cell Res. 246 (1999) 280-289
12. Gerritsen M.E., Williams A.J., Neish A.S., Moore S., Shi Y., and Collins T. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 2927-2932
13. Glick R.D., Swendeman A.L., Coffey D.C., Rifkind R.A., Marks P.A., Richon V.M., and La Quaglia M.P. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res. 59 (1999) 4392-4399
14. Glosh S. Regulation of inducible gene expression by the transcription factor NF-κB. Immunol. Res. 19 (1999) 183-189
15. Gozzini A., Rovida E., Sbarba P., Galimbert S., and Santini V. Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor - acute myeloid leukemia blasts. Cancer Res. 63 (2003) 8955-8961
16. Grignani F., Gelmetti V., Fanelli M., Rogaia D., De Matteis S., Ferrara F.F., Bonci D., Grignani F., Nervi C., and Pelicci P.G. Formation of PML/RAR alpha high molecular weight nuclear complexes through the PML coiled-coil region is essential for the PML/RAR alpha-mediated retinoic acid response. Oncogene 18 (1999) 6313-6321
17. Harper J.W., Adami G.R., Wei N., Keymarsi K., and Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75 (1993) 806-816
18. Hirano F., Tanaka H., Hirano Y., Hiramoto M., Handa H., Makino I., and Schneidereit C. Functional interference of Sp1 and NF-kappa B through the same DNA binding site. Mol. Cell. Biol. 18 (1998) 1266-1274
19. Hurley C.K. Electrophoresis of histones: a modified Panyim and Chalkley system for slab gels. Anal. Biochem. 80 (1977) 624-626
20. Jeannesson P., Ginot L., Manfait M., and Jardillier J.C. Induction of hemoglobin synthesis in human leukemic K 562 cells by adriamycin. Anticancer Res. 4 (1984) 47-51
21. Joseph J., Wajapeyee N., and Somasundaram K. Role of p53 status in chemosensitivity determination of cancer cells against histone deacetylase inhibitor sodium butyrate. Int. J. Cancer 115 (2005) 11-18
22. Kelly W.K., Richon V.M., O'Conor O., Curley T., MacGregore-Curtelli B., Tong W., Klang M., Schwartz L., Richardson S., Rosa E., Drobnjak M., Cordon-Cordo C., Chiao J.H., Rifkind R., Marks P.A., and Scher H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9 (2003) 3578-3588
23. Kiernan R., Bres V., Ng R.W., Coudart M.P., El Messaoudi S., Sardet C., Jin D.Y., Emiliani S., and Benkirane M. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J. Biol. Chem. 278 (2003) 2758-2766
24. Kosugi H., Towatari M., Hatano S., Kitamura K., Kiyoi H., Kinoshita T., Tanimoto M., Murate T., Kawashima K., Saito H., and Naoe T. Histone deacetylase inhibitors are potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia 13 (1999) 1316-1324
25. Kouzarides T. Histone methylation in transcriptional control. Curr. Opin. Genet. Dev. 12 (2002) 198-209
26. Kouzarides T. Wellcome Trust Award Lecture. Chromatin-modifying enzymes in transcription and cancer. Biochem. Soc. Trans. 31 (2003) 741-743
27. Kwon S.H., Ahn S.H., Kim Y.K., Bae G.U., Yoon J.W., Hong S., Lee H.Y., Lee Y.W., and Han J.W. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J. Biol. Chem. 277 (2002) 2073-2080
28. Lagger G., Doetzlhofer A., Schuettengruber B., Haidweger E., Simboeck E., Tischler J., Chiocca S., Suske G., Rotheneder H., Wintersberger E., and Seiser C. The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol. Cell. Biol. 23 (2003) 2669-2679
29. Lin R.J., Egan D.A., and Evans R.M. Molecular genetics of acute promyelocytic leukemia. Trends Genet. 15 (1999) 197-202
30. Marks P.A., Richon V.M., Breslow R., and Rifkind R.A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13 (2001) 477-483
31. Marks P.A., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1 (2001) 194-202
32. Minucci S., Nervi C., Lo Coco F., and Pelicci P.G. Histone deacetylase: a common molecular target for differentiation treatment of acute myeloid leukemias. Oncogene 20 (2001) 3110-3115
33. Newmark H.L., Lupton J.R., and Young C.W. Butyrate as a differentiating agent: pharmacokinetics, analogues and current status. Cancer Lett. 78 (1994) 1-5
34. Quivy V., and Van Lint C. Regulation at multiple levels of NF-κB-mediated transactivation by protein acetylation. Biochem. Pharmacol. 68 (2004) 1221-1229
35. Peart M.J., Tainton K.M., Ruefli A.A., Dear A.E., Sedelies K.A., O'Reilly L.A., Waterhouse N.J., Trapani J.A., and Johnstone R.W. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 63 (2003) 4460-4471
36. Redner R.L., Wang J., and Liu J.M. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 94 (1999) 793-802
37. Rao J., Zhang F., Donnelly R.J., Spector N.L., and Studzinski G.P. Truncation of Sp1 transcription factor by myeloblastin in undifferentiated HL-60 cells. J. Cell. Physiol. 175 (1999) 121-128
38. Richon V.M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R.A., and Marks P.A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 3003-3007
39. Richon V.M., Sandhoff T.W., Rifkind R.A., and Marks P.A. Histone deacetylase inhibitor selectivity induces p21 WAF1 expression and generated histone acetylation. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 10014-10169
40. Rivero J.A., and Adunyah S.E. Sodium butyrate stimulates PKC activation and induces differential expression of certain PKC isoforms during erythroid differentiation. Biochem. Biophys. Res. Commun. 248 (1998) 664-668
41. Roth S.Y., Denu J.M., and Allis C.D. Histone acetyltransferase. Annu. Rev. Biochem. 70 (2001) 81-120
42. Saccani S., Pantano S., and Natoli G. Two waves of nuclear factor κB recruitment to target promoters. J. Exp. Med. 193 (2001) 1351-1359
43. Sasakawa Y., Naoe Y., Inoue T., Sasakawa T., Matsuo M., Manda T., and Mutoh S. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem. Pharmacol. 64 (2002) 1079-1090
44. Savickiene J., Treigyte G., Magnusson K.-E., and Navakauskiene R. p21 (Waf1/Cip1) and FasL gene activation via Sp1 and NFκB is required for leukemia cell survival but not for cell death induced by diverse stimuli. Int. J. Biochem. Cell Biol. 37 (2005) 784-796
45. Scott E.W., Simon M.C., Anastasi J., and Singh H. Requirement of transcription factor PU.1 in the development of multiple haematopoietic lineages. Science 265 (1994) 1573-1577
46. Sowa Y., Orita T., Minamikawa S., Nakano K., Mizuno T., Nomura H., and Sakai T. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem. Biophys. Res. Commun. 241 (1997) 142-150
47. Strahl B.D., and Allis C.D. The language of covalent histone modifications. Nature 403 (2000) 41-45
48. Treigyte G., and Gineitis A. Specific changes in the biosynthesis and acetylation of nucleosomal histones in the early stages of embryogenesis of sea urchin. Exp. Cell Res. 121 (1979) 127-134
49. Vigushin D.M., and Combers R.C. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 1 (2002) 1-13
50. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
51. Wolffe A.P., Wong J., and Pruss D. Activators and repressors: making use of chromatin to regulate transcription. Genes Cells 2 (1997) 291-302
52. Vrana J.A., Decker R.H., Johnson C.R., Wang Z., Jarvis W.D., Richon V.M., Eginger M., Fisher P.B., and Grant S. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and independent of p53. Oncogene 18 (1999) 7016-7025
53. Yoshida M., Furumai R., Nishiyama M., Komatsu Y., Nishino N., and Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol. Suppl: 1 (2001) S20-S26
54. Yoshida M., Shimazu T., and Matuyama A. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets. Prog. Cell Cycle Res. 5 (2003) 269-278